{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-014572","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.343176+00:00","generated_at":"2026-06-15T01:20:28.160915+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Reviva Q1 net loss $6.6M; cash to fund ops through Q3 2023; Phase 3 topline data mid-2023","bullets":["Net loss of $6.6M ($0.30/shr) vs $7.4M ($0.40) in Q1 2022; cash $11.3M at Mar 31, 2023, down from $18.5M.","Cash sufficient to fund current plans through Q3 2023; additional financing needed for Phase 2a studies.","Over 60% of ~400 patients enrolled in Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.","Brilaroxazine lipogel showed proof-of-concept in psoriatic mouse model; IND for psoriasis expected in 2024.","May initiate Phase 2a studies in bipolar, MDD, and ADHD in H2 2023 subject to additional financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-014572","json":"https://secwatch.observer/filing/0001437749-23-014572.json","markdown":"https://secwatch.observer/filing/0001437749-23-014572.md","text":"https://secwatch.observer/filing/0001437749-23-014572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/0001437749-23-014572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/rvph20230512_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:20:28.160915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9af13ca866221f15b184dd0e63ceb00ddacd2e8","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the first quarter ended March 31, 2023 results: net income approximately $6.6 million, EPS $0.30 per share.","evidence_excerpt":"The Company reported a net loss of approximately $6.6 million, or $0.30 per share, for the three months ended March 31, 2023, compared to a net loss of approximately $7.4 million, or $0.40 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/0001437749-23-014572-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"approximately $6.6 million"},{"label":"EPS","value":"$0.30 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}